Search Results
May 15, 2026, 09:59 ET Datar Cancer Genetics reçoit l'autorisation de la FDA des États-Unis pour CellDx-Tissue, un test de profilage génomique complet pour les tumeurs solides utilisant l'ADN et l'ARN
vise à fournir des informations sur les variants somatiques à nucléotide unique (SNV), les petites insertions et délétions (InDels), l'amplification du gène ERBB2 et les fusions de gènes impliquant ALK, RET et ROS1. CellDx-Tissue est un test à site unique réalisé dans le laboratoire
More news about: Datar Cancer Genetics
May 14, 2026, 19:10 ET Ecovyst Completes Term Loan Amendment and Increase
result of new information, future developments or otherwise, except as may be required by applicable law.For more information:Gene Shiels – Senior Director of Investor Relations(484) 617 [email protected]
More news about: Ecovyst Inc.
May 14, 2026, 16:40 ET Atrium Therapeutics Reports First Quarter 2026 Financial Results
amended.About PRKAG2 SyndromePRKAG2 syndrome is a rare, autosomal dominant, early-onset cardiomyopathy caused by mutations in the PRKAG2 gene, which encodes the Gamma 2 regulatory subunit of AMPK. Mutations enhance AMPK activity leading to abnormal glycogen accumulation in heart muscle cells
More news about: Atrium Therapeutics
May 14, 2026, 16:31 ET Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform
infrastructure, or specialized personnel required by conventional NMR instrumentation. The Company's platform supports applications across bioprocessing, cell and gene therapy development, and clinical diagnostics. For more information, visit
More news about: Valion Bio, Inc.
May 14, 2026, 16:13 ET American Society of Gene and Cell Therapy Awards Beverly L. Davidson, PhD, Outstanding Achievement Award
understand realistic expectations for gene‑based medicine."Dr. Davidson's contributions truly exemplify the spirit of the Outstanding Achievement Award. She has helped define what's possible in gene therapy," said David Barrett, CEO, American Society of Gene & Cell Therapy. "This recognition
More news about: Children's Hospital of Philadelphia
May 14, 2026, 12:57 ET Hidden small RNA determines if cholera bacterium can infect humans
previously compared bacterial DNA from patient and environmental samples, identifying variation in a gene called ompU. In this study, they discovered that the critical factor for infection was not the gene itself, but a small RNA encoded within it. Variations in this RNA had widespread effects on the
More news about: St. Jude Children's Research Hospital
May 14, 2026, 11:48 ET Datar Cancer Genetics Receives Landmark US FDA Clearance for CellDx-Tissue, a Comprehensive Genomic Profiling Assay for Solid Tumors Using DNA + RNA
and is intended to provide information on somatic single nucleotide variants (SNVs), small insertions and deletions (InDels), ERBB2 gene amplification, and gene fusions involving ALK, RET and ROS1. CellDx-Tissue is a single-site assay performed at Datar Cancer Genetics' CAP-
More news about: Datar Cancer Genetics
May 14, 2026, 11:39 ET Datar Cancer Genetics Receives Landmark US FDA Clearance for CellDx-Tissue, a Comprehensive Genomic Profiling Assay for Solid Tumors Using DNA + RNA
and is intended to provide information on somatic single nucleotide variants (SNVs), small insertions and deletions (InDels), ERBB2 gene amplification, and gene fusions involving ALK, RET and ROS1. CellDx-Tissue is a single-site assay performed at Datar Cancer Genetics' CAP-
More news about: Datar Cancer Genetics
May 14, 2026, 10:30 ET Pharmaceutical Drug Delivery Market worth $2,922.82 billion by 2031 | MarketsandMarkets™
onset of action, higher bioavailability, and accurate dosing, making them essential for complex therapies, such as monoclonal antibodies, vaccines, and gene and cell therapies. Additionally, the growing adoption of long-acting injectables, depot formulations, and targeted delivery systems is improving therapeutic
More news about: MarketsandMarkets
May 14, 2026, 09:00 ET A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a Premier Longevity Forum: Inside Avaí Bio's Cell-Based Platform Approach
continued to expand its CRISPR/Cas9 gene-editing platform across multiple therapeutic verticals — including the autologous and allogeneic cell therapy programs that have continued to define the cutting edge of the cell-therapy category. The Company's positioning at the gene-editing layer of the broader cell-based
More news about: Equity Insider
May 14, 2026, 09:00 ET Tri-City Medical Center Unveils Redesigned Emergency Department, Powered by $5.2 Million Community Investment
the door."Tri-City has served North County for more than six decades, and our commitment to this community has never been stronger," said Gene Ma, MD, FACEP, President and CEO of Tri-City Medical Center. "This Emergency Department is a turning point. It reflects what is possible when a
More news about: Tri-City Medical Center
May 14, 2026, 09:00 ET Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
presenting data this week featuring its off-the-shelf CAR T-cell programs FT819, FT839, and FT836 at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting to be held in Boston, MA, May 11–15, 2026."We are excited to highlight our leadership in delivering off-the-shelf
More news about: Market News Updates
May 14, 2026, 08:00 ET Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data on the Company's diabetes gene therapy drug candidate at the 2026 American Society of Gene and Cell Therapy
More news about: Genprex, Inc.
May 14, 2026, 07:30 ET Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment
delayed menopause.5 TP53 is a well-recognized prognostic marker for EC; >50% of advanced or recurrent EC tumors are TP53wt (gene for tumor protein P53; wild-type), and ~40%-55% are both TP53wt and mismatch repair-proficient (pMMR).6-8 While immune checkpoint
More news about: Karyopharm Therapeutics Inc.
May 14, 2026, 07:10 ET REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases,
More news about: REGENXBIO Inc.
May 14, 2026, 07:00 ET GEMMABio Unveils Duchenne Muscular Dystrophy (DMD) Program and Presents Preclinical Data for Next‑Generation Gene Therapies for DMD and Spinal Muscular Atrophy Type 1 (SMA1) at the ASGCT 2026 Annual Meeting
supporting candidate declaration for GB703, a novel, potential gene therapy for Duchenne muscular dystrophy (DMD). The company also publicized the presentation of comprehensive preclinical data for GB221, a next-generation, investigational gene therapy for spinal muscular atrophy type 1 (SMA1). Juliette
More news about: GEMMA Biotherapeutics
May 14, 2026, 07:00 ET REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202
Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for
More news about: REGENXBIO Inc.
May 14, 2026, 06:00 ET ASGCT and Orphan Therapeutics Accelerator Launch CGTxchange -- A First-of-Its-Kind Marketplace to Reactivate Promising Shelved Cell and Gene Therapy Programs
cell and gene therapy assets, operated as a joint venture between the American Society of Gene & Cell Therapy (ASGCT) and Orphan Therapeutics Accelerator (OTXL). The platform is designed to help sponsors, funders, investors, and partners discover, evaluate, and reactivate shelved cell and gene therapy
More news about: Orphan Therapeutics Accelerator (OTXL) and The American Society of Gene & Cell Therapy (ASGCT)
May 14, 2026, 06:00 ET Ring Therapeutics® Presents its Vector Conjugate and VectorBricks™ Manufacturing Platforms at the 29th Annual American Society of Gene & Cell Therapy Conference
vitro manufacturing technology. The data, which are being presented as a poster and an oral presentation at the 29th Annual American Society of Gene & Cell Therapy (ASGCT) conference, highlight significantly increased cargo capacity for the delivery of oligonucleotides using targetable vectors
More news about: Ring Therapeutics
May 13, 2026, 13:37 ET Shield AI 與 Thunder Tiger 合作，在台灣擴展 Hivemind 海上自主能力
賦予遏制衝突所需的非對稱戰力，這亦是支援台灣整體策略的一部分。」該協議確立分階段的整合與測試方法，包括基於模擬的測試、硬件在環整合，以及實車測試。 目標是驗證多個自主系統能否在 Thunder Tiger 的不同平台上，以協調一致的團隊模式共同運作。Thunder Tiger Corp. 董事兼總經理 Gene Su 表示：「Thunder Tiger 已建構一系列專為真實作戰情境設計的無人系統產品，由海岸防禦至跨領域任務一應俱全。 引入 Hivemind 後，我方平台得以擁有自主決策能力，既可獨立執行複雜任務，亦可融入協同團隊之中共同行動。 我們認為此合作是一個契機，有助提升台灣的國防工業基礎，並為部隊提供性能更強的自主系統。」Hivemind
More news about: Shield AI
May 13, 2026, 11:49 ET Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1
platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam's suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise,
More news about: Alpha-1 Foundation
May 13, 2026, 10:45 ET Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility
products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited.For more information visit:
More news about: Piramal Pharma Solutions
May 13, 2026, 10:37 ET Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility
products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited.For more information visit:
More news about: Piramal Pharma Solutions
May 13, 2026, 08:30 ET Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates
covering ATR-12, the Company's lead product candidate being developed for Netherton syndrome.Announced poster presentation at American Society of Gene and Cell Therapy Annual Meeting (ASGCT) 2026 highlighting ATR-01 preclinical data and the broader potential of Azitra's engineered live biotherapeutic
More news about: Azitra, Inc.
May 13, 2026, 08:30 ET Greenland Mines Ltd to Present at CMI Summit 5 as Western-Aligned PGM and Critical Minerals Developer
of the Skaergaard Project in Southeast Greenland, one of the largest undeveloped palladium, gold, and platinum deposits in the world; and 2) Cell and Gene Therapy, including Klotho's KLTO-202 primary indication for ALS. The Company holds, through its recent acquisition of Greenland Mines Corp., the Skaergaard
More news about: Greenland Mines Ltd